Cancer Driving Mutations in Endometriosis Lesions and Development of Progesterone Resistance

Running, not enrolling

Conditions studied: Endometriosis, Endometrial Diseases

In brief

This study will test the hypothesis that the molecular changes present in ectopic endometriosis lesions correlate with progesterone-resistant disease (using the criteria defined in this study) and are present in matched eutopic endometrium.

Key facts

Study ID: NCT03756480
Run by: Johns Hopkins University
People needed: 135
Starts: 2020-10-01
Expected to finish: 2026-10-01
Last updated by the study team: 2026-06-09

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Signed informed consent.
Gender: female.
Age: 18-45 years at the time of signing consent.
Clinical or surgical diagnosis of endometriosis undergoing laparoscopy.
Controls may not have clinical or surgical diagnosis of endometriosis.
Regular menstrual cycles.
BMI between 18-40 kg/m2.
Sexually active or have had a previous vaginal exam that used a speculum.
English speaking

You may not qualify if…

Use of any kind of steroidal therapy including oral contraceptives, Norplant, estrogen replacement/supplemental therapy, androgens (Danazol, Cyclomen, Danocrine, testosterone) or progesterone. She may not be taking or be on Celebrex.
Pregnant.
Presence of pelvic infection.
Mullerian anomalies with absence of a cervix.
History of cancer of the reproductive tract.
Presence of undiagnosed uterine bleeding.
Treatment with intrauterine device (IUD) or progestin-containing intrauterine device.

Where it is running

Yale School of Medicine — New Haven, Connecticut, United States
Johns Hopkins Hospital — Baltimore, Maryland, United States
Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.